AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20847065 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg retard administered at 19:00 hours the day before the operation and at 06:00 hours on the day of the operation.
Number of subjects: 101
Study 20847065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified).
Number of subjects: 101
Study 20847065 — intervention group
Group type: EXPERIMENTAL
Intervention: Late remote ischaemic preconditioning (L‐RIPC).
Number of subjects: 101
Study 20847065 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol group.
Number of subjects: 101
Study 17624688 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence reinforcement (AR)
Number of subjects: 368
Study 17624688 — intervention group
Group type: EXPERIMENTAL
Intervention: New Uses of cocaine (measured by algorithm to BE)
Number of subjects: 368
Study 17624688 — intervention group
Group type: COMPARATOR
Intervention: Qualitative urinalysis
Number of subjects: 368
Study 17624688 — intervention group
Group type: COMPARATOR
Intervention: Benzoylecgonine concentration (BE)
Number of subjects: 368
Study 16126652 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 29
Study 16126652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12843894 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% drops twice the day before and twice on the day of the operation
Number of subjects: 40
Study 12843894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10403222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy
Number of subjects: 45
Study 10403222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1957331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of 0.6 mg digoxin
Number of subjects: 3
Study 1957331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of 1.2 mg digoxin
Number of subjects: 3
Study 1957331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (p.o.) administration of 0.6 mg digoxin
Number of subjects: 3
Study 1957331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (p.o.) administration of 1.2 mg digoxin
Number of subjects: 3
Study 6313028 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (6 mg/kg) while standing
Number of subjects: 6
Study 6313028 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (6 mg/kg) while supine
Number of subjects: 6
Study 6313028 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) while standing
Number of subjects: 6
Study 6313028 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (6 mg/kg) while standing vs supine
Number of subjects: 6
Study 31488373 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1800
Study 31488373 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1800
Study 31488373 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI in patients with three-vessel disease
Number of subjects: 1800
Study 31488373 — intervention group
Group type: COMPARATOR
Intervention: CABG in patients with three-vessel disease
Number of subjects: 1800
Study 31488373 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI in patients with left main coronary artery disease
Number of subjects: 1800
Study 31488373 — intervention group
Group type: COMPARATOR
Intervention: CABG in patients with left main coronary artery disease
Number of subjects: 1800
Study 29359722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 62
Study 29359722 — intervention group
Group type: COMPARATOR
Intervention: Standard infusion therapy (Control)
Number of subjects: 62
Study 24965957 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates method with NSAID treatment
Number of subjects: 60
Study 24965957 — intervention group
Group type: COMPARATOR
Intervention: NSAID treatment without Pilates
Number of subjects: 60
Study 23818768 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily antioxidant and essential polyunsaturated fatty acid supplement (two pills) for 3 months (+S)
Number of subjects: 97
Study 23818768 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (‐NS)
Number of subjects: 97
Study 19863602 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-fibrin glue
Number of subjects: 29
Study 19863602 — intervention group
Group type: COMPARATOR
Intervention: Collagen implant
Number of subjects: 29
Study 19995507 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced operator with experienced assistant using rubber dam tooth-isolation method
Number of subjects: 804
Study 19995507 — intervention group
Group type: COMPARATOR
Intervention: Inexperienced operator with inexperienced assistant
Number of subjects: 804
Study 19995507 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced operator with inexperienced assistant
Number of subjects: 804
Study 19995507 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced assistant with inexperienced operator
Number of subjects: 804
Study 17535134 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual imagery task
Number of subjects: 186
Study 17535134 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory imagery task
Number of subjects: 186
Study 17535134 — intervention group
Group type: COMPARATOR
Intervention: Auditory imagery task
Number of subjects: 186
Study 17535134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimagery craving induction (chocolate deprivation and exposure to chocolate cues)
Number of subjects: 186
Study 15470881 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactmer (RM) - giomer
Number of subjects: 75
Study 15470881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II (FJ) - conventional glass ionomer
Number of subjects: 75
Study 15470881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC (FL) - resin modified glass ionomer
Number of subjects: 75
Study 15470881 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract AP (DY) - compomer
Number of subjects: 75
Study 15470881 — intervention group
Group type: COMPARATOR
Intervention: Spectrum TPH (SP) - non-fluoride releasing composite
Number of subjects: 75
Study 11425834 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg)
Number of subjects: 37
Study 11425834 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin B(6))
Number of subjects: 37
Study 11720628 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 0
Study 11720628 — intervention group
Group type: COMPARATOR
Intervention: Standard medical and surgical therapy
Number of subjects: 0
Study 7592200 — intervention group
Group type: EXPERIMENTAL
Intervention: Running below lactate threshold (LT)
Number of subjects: 24
Study 7592200 — intervention group
Group type: COMPARATOR
Intervention: Running above lactate threshold (LT)
Number of subjects: 24
Study 7592200 — intervention group
Group type: COMPARATOR
Intervention: Running above LT
Number of subjects: 24
Study 7592200 — intervention group
Group type: EXPERIMENTAL
Intervention: Running below LT
Number of subjects: 24
Study 1848972 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 213
Study 1848972 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 213
Study 1848972 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 213
Study 1848972 — intervention group
Group type: EXPERIMENTAL
Intervention: Comedocarcinoma
Number of subjects: 213
Study 1848972 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncomedocarcinoma
Number of subjects: 213
Study 7048915 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir applied topically four times daily for 10 days
Number of subjects: 43
Study 7048915 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied topically four times daily for 10 days
Number of subjects: 43
Study 31511385 — intervention group
Group type: EXPERIMENTAL
Intervention: V160 vaccine
Number of subjects: 6
Study 29513303 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum 3 times a day postoperatively
Number of subjects: 89
Study 29513303 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 89
Study 27802585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2 mA/20 min for 10 sessions)
Number of subjects: 12
Study 27802585 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS (2 mA/20 min for 10 sessions)
Number of subjects: 12
Study 24184576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin (16 IU)
Number of subjects: 50
Study 24184576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22044433 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (400 mg/day, titrated to 600 mg/day)
Number of subjects: 0
Study 22044433 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine (4 mg/day)
Number of subjects: 0
Study 22044433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20688811 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological training for 6 months
Number of subjects: 14
Study 18199844 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD with a target creatinine clearance > or =60 L/wk/1.73 m(2)
Number of subjects: 965
Study 18199844 — intervention group
Group type: COMPARATOR
Intervention: Standard 4 x 2L continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 965
Study 18199844 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume removal
Number of subjects: 965
Study 15698708 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety harness
Number of subjects: 60
Study 15698708 — intervention group
Group type: EXPERIMENTAL
Intervention: Light touch
Number of subjects: 60
Study 15698708 — intervention group
Group type: COMPARATOR
Intervention: No visual information
Number of subjects: 60
Study 12960652 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigastric impedance measurement in patients with gastrointestinal diseases
Number of subjects: 61
Study 12960652 — intervention group
Group type: COMPARATOR
Intervention: Epigastric impedance measurement in healthy infants (control group)
Number of subjects: 61
Study 10533859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioners
Number of subjects: 1453
Study 10533859 — intervention group
Group type: COMPARATOR
Intervention: Junior doctors
Number of subjects: 1453
Study 8627061 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐n3 (IFN‐alpha n3) 1 mega‐IU (MIU)/dose
Number of subjects: 20
Study 8627061 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐n3 (IFN‐alpha n3) 5 MIU/dose
Number of subjects: 20
Study 8627061 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐n3 (IFN‐alpha n3) maximum tolerated dose
Number of subjects: 20
Study 1471382 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pantoprazole o.m.
Number of subjects: 219
Study 1471382 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole o.m.
Number of subjects: 219
Study 1471382 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg pantoprazole o.m.
Number of subjects: 219
Study 6363731 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention
Number of subjects: 935
Study 6363731 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 935
Study 31133558 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial random noise stimulation (tRNS) over visual areas coupled with visual training for 10 days
Number of subjects: 0
Study 31133558 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (not specified)
Number of subjects: 0
Study 31133558 — intervention group
Group type: COMPARATOR
Intervention: Anodal stimulation (not specified)
Number of subjects: 0
Study 29360237 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-year lifestyle intervention (6 face-to-face sessions and 2 telephone calls in the first year, 2 individual sessions and 2 telephone calls in subsequent years)
Number of subjects: 1180
Study 29360237 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-year lifestyle intervention (specifically for overweight women)
Number of subjects: 1180
Study 29360237 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-year lifestyle intervention
Number of subjects: 1180
Study 29360237 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1180
Study 29360237 — intervention group
Group type: COMPARATOR
Intervention: Standard care (specifically for overweight women)
Number of subjects: 1180
Study 27328975 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE Plus intervention
Number of subjects: 152
Study 27328975 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 152
Study 24820928 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walking test (6MWT)
Number of subjects: 74
Study 24820928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry
Number of subjects: 74
Study 24820928 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 74
Study 24820928 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 74
Study 21778151 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 29
Study 21778151 — intervention group
Group type: COMPARATOR
Intervention: Bupropion XL
Number of subjects: 29
Study 20108156 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.5% bupivacaine (50 mg)
Number of subjects: 50
Study 20108156 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of sterile water
Number of subjects: 50
Study 18614815 — intervention group
Group type: EXPERIMENTAL
Intervention: High PUFA diet
Number of subjects: 14
Study 18614815 — intervention group
Group type: COMPARATOR
Intervention: High SFA diet
Number of subjects: 14
Study 15641037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 70 mg/m2 on Day 1, etoposide 50 mg/m2 on Days 1-3, and gemcitabine 1000 mg/m2 on Days 1 and 8 (PEG)
Number of subjects: 140
Study 15641037 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 70 mg/m2 on Day 1 plus gemcitabine 1250 mg/m2 on Days 1 and 8 (PG)
Number of subjects: 140
Study 15641037 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG regimen
Number of subjects: 140
Study 15641037 — intervention group
Group type: COMPARATOR
Intervention: PG regimen
Number of subjects: 140
Study 15553066 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN-s (pegylated interferon alpha)
Number of subjects: 0
Study 15553066 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with ribavirin
Number of subjects: 0
Study 15553066 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with PEG-IFN-s
Number of subjects: 0
Study 10470391 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 10 micrograms/kg
Number of subjects: 228
Study 10470391 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 20 micrograms/kg
Number of subjects: 228
Study 10470391 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 228
Study 10470391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of droperidol
Number of subjects: 228
Study 8759084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg warfarin
Number of subjects: 51
Study 8759084 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg aspirin
Number of subjects: 51
Study 8759084 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional warfarin therapy
Number of subjects: 51
Study 8290745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 micrograms day-1) via Diskhaler inhaler
Number of subjects: 585
Study 8290745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 micrograms day-1) via pressurized inhaler
Number of subjects: 585
Study 8290745 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (1000 micrograms day-1) via pressurized inhaler
Number of subjects: 585
Study 3548312 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch-rich foods (beans, lentils, rice, spaghetti, potato, bread)
Number of subjects: 18
Study 3548312 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meals (isoglucido-lipido-protidic)
Number of subjects: 18
Study 29743224 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT tools and educational materials
Number of subjects: 23
Study 29743224 — intervention group
Group type: COMPARATOR
Intervention: HIT tools, educational materials, and individualized implementation support with a practice coach
Number of subjects: 23
Study 27575820 — intervention group
Group type: EXPERIMENTAL
Intervention: Y90 radioembolization
Number of subjects: 179
Study 27575820 — intervention group
Group type: COMPARATOR
Intervention: cTACE
Number of subjects: 179
Study 25854786 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy + Coenzyme Q10 (CoQ10)
Number of subjects: 100
Study 25854786 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 100
Study 24134498 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 329
Study 21816779 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA)
Number of subjects: 152
Study 21816779 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA)
Number of subjects: 152
Study 21816779 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA/PUFA ratio
Number of subjects: 152
Study 19451658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of Falling (FoF) group
Number of subjects: 100
Study 19451658 — intervention group
Group type: COMPARATOR
Intervention: No Fear of Falling (no-FoF) group
Number of subjects: 100
Study 16681406 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft palate repair first, followed by hard palate and lip repair 3 months later
Number of subjects: 47
Study 16681406 — intervention group
Group type: COMPARATOR
Intervention: Hard palate and lip repair first, followed by soft palate repair 3 months later
Number of subjects: 47
Study 16681406 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft palate repair first
Number of subjects: 47
Study 16681406 — intervention group
Group type: COMPARATOR
Intervention: Hard palate and lip repair first
Number of subjects: 47
Study 14647988 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT imaging
Number of subjects: 27
Study 14647988 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 27
Study 14647988 — intervention group
Group type: COMPARATOR
Intervention: FDG-PET alone
Number of subjects: 27
Study 14647988 — intervention group
Group type: COMPARATOR
Intervention: CT and FDG-PET read side by side
Number of subjects: 27
Study 14647988 — intervention group
Group type: COMPARATOR
Intervention: Regional lymph node involvement
Number of subjects: 27
Study 11584209 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate solution (0.025 mg/kg)
Number of subjects: 15
Study 11584209 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 15
Study 10561250 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (50 mg/m(2) IV over 15 minutes) and docetaxel (75 mg/m(2) IV over 1 hour) every 14 days for four cycles
Number of subjects: 42
Study 10561250 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and docetaxel (3-week schedule)
Number of subjects: 42
Study 8018023 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS preface statement
Number of subjects: 400
Study 8018023 — intervention group
Group type: COMPARATOR
Intervention: General preface statement
Number of subjects: 400
Study 8018023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prefaces (AIDS and General)
Number of subjects: 400
Study 8018023 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders vs Nonresponders
Number of subjects: 400
Study 2689679 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine 2 mg or vindesine 3 mg per week, prednisolone 20 to 30 mg per day, and partly 6-mercaptopurine 50 to 100 mg, combined with allopurinol 200 to 300 mg per day for 2 to 3 weeks.
Number of subjects: 83
Study 2689679 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with busulfan or other alkylating agents.
Number of subjects: 83
Study 5677210 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with tolbutamide, chlorpropamide, or metformin
Number of subjects: 0
Study 5677210 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 0
Study 5677210 — intervention group
Group type: EXPERIMENTAL
Intervention: Total starvation in obese subjects
Number of subjects: 0
Study 30719981 — intervention group
Group type: EXPERIMENTAL
Intervention: MiStent (sirolimus-eluting stent)
Number of subjects: 1398
Study 30719981 — intervention group
Group type: COMPARATOR
Intervention: XIENCE (everolimus-eluting stent)
Number of subjects: 1398
Study 29656663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine (84 mg)
Number of subjects: 68
Study 29656663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 26581034 — intervention group
Group type: EXPERIMENTAL
Intervention: BTHC blood bags
Number of subjects: 0
Study 26581034 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control phase)
Number of subjects: 0
Study 26581034 — intervention group
Group type: EXPERIMENTAL
Intervention: DEHP-containing blood bags
Number of subjects: 0
Study 25173516 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib (160 mg once daily)
Number of subjects: 13026
Study 25173516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study 22447213 — intervention group
Group type: EXPERIMENTAL
Intervention: Short consent form (3602 words, 5 pages)
Number of subjects: 581
Study 22447213 — intervention group
Group type: COMPARATOR
Intervention: Standard consent form (10,459 words, 11 pages)
Number of subjects: 581
Study 20429946 — intervention group
Group type: EXPERIMENTAL
Intervention: Population based screening by mail
Number of subjects: 187
Study 20429946 — intervention group
Group type: COMPARATOR
Intervention: General practice recruitment
Number of subjects: 187
Study 18209107 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach facilitation intervention
Number of subjects: 54
Study 15792400 — intervention group
Group type: EXPERIMENTAL
Intervention: New 625 mg nelfinavir tablet (test formulation)
Number of subjects: 52